Showing results (311-320 of 470) with videos related to
Sort By:
Pageof 47
Breast Cancer Research : BCR|January 3, 2024
Identification of a Notch transcriptomic signature for breast cancerEike-Benjamin Braune, Felix Geist, Xiaojia Tang, et al.Steroids|August 28, 2014
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozoleJames N Ingle, Krishna R Kalari, Aman U Buzdar, et al.Cancer Science|March 9, 2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trialsMasakazu Toi, Kenichi Inoue, Norikazu Masuda, et al.NPJ Breast Cancer|September 1, 2017
Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genesDuan Liu, Ming-Fen Ho, Daniel J Schaid, et al.The Oncologist|September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2005
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trialsDaniel J Sargent, Harry S Wieand, Daniel G Haller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal CancerTimothy J Iveson, Alberto F Sobrero, Takayuki Yoshino, et al.Cancer Research|April 1, 2010
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancerJames N Ingle, Aman U Buzdar, Daniel J Schaid, et al.Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.Pageof 47